Bio Nebraska is a non-profit, membership-based trade association with a diversified membership including entities from all segments of Nebraska’s bioscience industry.
Bio Nebraska is tasked with promoting, connecting and catalyzing the biosciences in Nebraska in an effort to make Nebraska the best state for bioscience organizations to grow and thrive.
NETWORKING
Bring people together to form valuable connections and relationships
ADVOCACY
Stimulate growth and positive change by championing Nebraska’s biosciences
WORKFORCE DEVELOPMENT & EDUCATION
Aid in the development of a highly educated and diverse workforce
Join us in our effort to expand the biosciences in our state. See the benefits of membership or contact us to discuss the opportunities Bio Nebraska may be able to provide for you.
UPCOMING EVENTS
Women in Bio: The Benefit of Fractional Talent Handling Backend Operations
Horsepower Today
September 11, 2024
Omaha, Nebraska Read more
Bio Innovations Midwest 2024
World Bio Markets
September 24-25, 2024
Omaha, Nebraska Read more
LATEST NEWS
U.S. News ranks UNMC a top medical school in primary care training
The University of Nebraska Medical Center (UNMC), a member of Bio Nebraska, announced that it has been named by U.S. News & World Report a Tier 1 institution for primary care training. Read more
Welcome High Volume Oxygen
We are excited to welcome new Bio Nebraska member, High Volume Oxygen. Read more
Welcome Bullseye Gx
We are excited to welcome new Bio Nebraska member, Bullseye Gx. Read more
Deadline Approaches to Register for Ag and Economic Development Summit
The Ag & Economic Development Summit: One Nebraska will take place August 7-9, in Kearney, Neb., and will include a breakout session, “Nebraska’s New Vision for Economic Development,” that will feature Bio Nebraska. The deadline to register is July 26. Read more
![](https://www.bionebraska.org/wp-content/uploads/2024/03/Sandoz-Logo-Sandoz-Blue-RGB-768x236.png)
Member Spotlight: Sandoz
For our July Member Spotlight we talked to Sandoz, a global leader in the generics and biosimilars markets with one of the broadest portfolios in the industry, reaching approximately 500 million patients every year in more than 100 markets.